- Trial phase
- Phase 2
- Time to market
- SPY003 is in Phase 2 with no regulatory filing yet. The next major readout (SKYLINE Part B combination induction data) is expected in 2027. Assuming positive Phase 2 and subsequent Phase 3 trials, potential approval would likely be several years away, likely 2029 or later.
- Why 5/10
- The next hard, dated catalyst is the SKYLINE Part B topline induction data for the pairwise combination regimens (SPY120, SPY130, SPY230), expected in 2027 (roughly 6-12 months from now). SPY003 is one of three components in Spyre's pipeline, but the combination strategy is central to the company's thesis. The impact score of 5 reflects a major program whose next binary catalyst is not precisely dated and is 6-12 months out, at a company with multiple programs and a strong cash runway.
The next major catalyst is SKYLINE Part B combination data expected in 2027, which will test whether pairing SPY003 with SPY001 (anti-alpha4beta7) or SPY002 (anti-TL1A) produces meaningfully better efficacy than monotherapy. Positive combination data would be a major derisking event for the entire platform; negative or underwhelming results would raise questions about the combination strategy's value proposition in a competitive IL-23 market. The company's strong cash runway into H2 2029 removes near-term financing risk.
Price Chart
Executive Summary
SPY003 is Spyre Therapeutics' extended half-life anti-IL-23 antibody for inflammatory bowel disease, currently in Phase 2 development. In September 2026, it met its primary endpoint in Part A of the SKYLINE trial for ulcerative colitis with a statistically significant 10-point RHI reduction (p<0.0001), completing proof-of-concept for all three of Spyre's IBD mechanisms. The drug's key differentiator is its ~85-day half-life, roughly triple that of marketed IL-23 inhibitors, potentially enabling quarterly or twice-yearly maintenance dosing. The stock trades near $99 with strong analyst support (mean PT $122.53) and a well-funded pipeline (~$1.47B cash). The next catalyst is the SKYLINE Part B combination data expected in 2027.
How It Works
SPY003 is an injectable monoclonal antibody that blocks IL-23, a protein that drives chronic inflammation in the gut. It is engineered with a YTE modification that makes it last much longer in the body (about 85 days half-life vs roughly 28 days for existing IL-23 blockers), which could allow patients to receive injections once every 3 to 6 months instead of every 4 to 8 weeks.
Trial Status
SPY003 completed Part A of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC), reporting positive 12-week induction topline data on September 8, 2026. The trial met its primary endpoint with a statistically significant 10.0-point reduction in Robart's Histopathology Index (RHI) score (p<0.0001). Secondary endpoints showed 20% clinical remission by modified Mayo Score and 30% endoscopic improvement. Safety was consistent with the IL-23 class. Part B of SKYLINE, which evaluates pairwise combinations of SPY003 with SPY001 (anti-alpha4beta7) and SPY002 (anti-TL1A), is enrolling ahead of schedule.
The Two-Sided Case
Upcoming Catalysts
- SKYLINE Part B topline induction data for pairwise combinations (SPY120, SPY130, SPY230) expected in 2027
- Potential initiation of Phase 3 program for SPY003 or combinations after Part B data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report